GE HealthCare

Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the capital required for debt repayments.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025

The purchase was funded by the proceeds of senior unsecured notes issued in the fourth quarter of 2025, together with new borrowings under a delayed draw term loan facility and cash on hand.

SEC original ↗GE HealthCare — 10-Q Quarterly report10-QOct 28, 2026

See Note 8, Borrowings for additional information on the borrowings.

SEC original ↗GE HealthCare — 10-Q Quarterly report10-QOct 28, 2026

In order to reflect the occurrence of the acquisition on January 1, 2025, the unaudited supplemental pro forma financial information includes adjustments to reflect the following: (i) incremental amortization expense based on the current preliminary fair values of the identifiable intangible assets; (ii) the additional interest expense associated with the issuance of debt to finance the acquisition; and (iii) the reclassification of transaction and other acquisition-related costs incurred during the three and nine months ended September 30, 2026, to the three and nine months ended September 30, 2025.

SEC original ↗GE HealthCare — 10-Q Quarterly report10-QOct 28, 2026

BORROWINGS The Company s borrowings include the senior unsecured notes and credit agreements detailed below.

SEC original ↗GE HealthCare — 10-Q Quarterly report10-QOct 28, 2026

Senior Unsecured Notes As of September 30, 2026, the Company s borrowings include $ 9,500 million aggregate principal amount of senior unsecured notes in nine series with maturity dates ranging from 2027 through 2052.

SEC original ↗GE HealthCare — 10-Q Quarterly report10-QOct 28, 2026

As a result of our increased R D investments, we are entering a new wave of innovation and, coupled with our focus on lean, we expect to accelerate top and bottom line growth.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025

GE HealthCare does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or dispositions, timing and magnitude of restructuring activities, and revaluation of strategic investments, amongst other items.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025

These forward-looking statements may include, but are not limited to, statements about the Company s business and expected financial performance, financial condition, and results of operations, including revenue, revenue growth, profit, taxes, earnings per share, and cash flows, and the Company s outlook the impacts of macroeconomic and market conditions, including the impact of tariffs and other trade restrictions, and volatility on the Company s business, operations, financial results, and financial position and on supply chains and the world economy and the Company s strategy, innovation, and investments.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025

In the second quarter of 2026, we made a strategic change to our executive leadership and to our segments, combining our Imaging and Advanced Visualization Solutions ( AVS ) businesses into a new operating and reportable segment, Advanced Imaging Solutions ( AIS ).

SEC original ↗GE HealthCare — 10-Q Quarterly report10-QOct 28, 2026

SEGMENT INFORMATION In the second quarter of 2026, we made a strategic change to our executive leadership and to our segments, combining our Imaging and AVS businesses into a new operating and reportable segment, Advanced Imaging Solutions.

SEC original ↗GE HealthCare — 10-Q Quarterly report10-QOct 28, 2026

Organic orders growth was 6% with growth across all segments Net income margin was 8.7% Adjusted earnings before interest and taxes (EBIT) margin* was 14.8% Diluted earnings per share (EPS) were $0.98 Adjusted EPS* was $1.07 Cash flow from operating activities was $593 million Free cash flow* was $483 million Excluding tariff impacts, margin and EPS would have exceeded prior year Raises the lower end of full-year 2025 Adjusted EPS* guidance range and reaffirms all other metrics Chicago, IL October 29, 2025 GE HealthCare (Nasdaq GEHC) today reported financial results for the third quarter ended September 30, 2025.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Adjusted EBIT margin* was 14.8% versus 16.3%, down 150 bps, with both measures impacted by tariffs, partially offset by benefits from volume and price.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Adjusted EPS* was $1.07 versus $1.14, down $0.06 from the prior year as both measures saw an impact from tariff expense.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Excluding tariff impacts, margin and EPS would have exceeded prior year.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025

2 Tariff assumptions for updated guidance Bi lateral U.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025

and China tariffs introduced this year continue and will rise on November 10, 2025 (to a rate of 54% for U.

SEC original ↗GE HealthCare — Earnings release (8-K exhibit)EX-99Oct 29, 2025